Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples
Asciutto, Katrin Christine LU ; Ernstson, Avalon LU
; Forslund, Ola
LU
and Borgfeldt, Christer
LU
(2018)
In Journal of Clinical Virology
101.
p.69-73
- Abstract
Background: In order to increase coverage in the organized cervical screening program, self-sampling with HPV analyses has been suggested. Objectives: The aim was to compare human papillomavirus (HPV) mRNA detection in vaginal and urine self-collected samples with clinician-taken cervical samples and the corresponding clinician-taken histological specimens. Study design: Self-collected vaginal, urine and clinician-taken cervical samples were analyzed from 209 women with the Aptima mRNA assay (Hologic Inc, MA, USA). Cervical cytology, colposcopy, biopsy and/or the loop electrosurgical excision procedure (LEEP) were performed in every examination. Results: The sensitivity of the HPV mRNA test in detecting high-grade squamous... (More)
Background: In order to increase coverage in the organized cervical screening program, self-sampling with HPV analyses has been suggested. Objectives: The aim was to compare human papillomavirus (HPV) mRNA detection in vaginal and urine self-collected samples with clinician-taken cervical samples and the corresponding clinician-taken histological specimens. Study design: Self-collected vaginal, urine and clinician-taken cervical samples were analyzed from 209 women with the Aptima mRNA assay (Hologic Inc, MA, USA). Cervical cytology, colposcopy, biopsy and/or the loop electrosurgical excision procedure (LEEP) were performed in every examination. Results: The sensitivity of the HPV mRNA test in detecting high-grade squamous intraepithelial lesions (HSIL)/adenocarcinoma in situ (AIS)/cancer cases was as follows: for the vaginal self-samples 85.5% (95% CI; 75.0–92.8), the urinary samples 44.8% (95% CI; 32.6–57.4), and for routine cytology 81.7% (95% CI; 70.7–89.9). For the clinician-taken cervical HPV samples the sensitivity of the HPV mRNA test in detecting HSIL/AIS/cancer was 100.0% (95% CI; 94.9–100.0). The specificity of the HPV mRNA was similar for the clinician-taken cervical HPV samples and the self-samples: 49.0% vs. 48.1%. The urinary HPV samples had a specificity of 61.9% and cytology had a specificity of 93.3%. Conclusion: The sensitivity of the Aptima HPV mRNA test in detecting HSIL/AIS/cancer from vaginal self-samples was similar to that of routine cytology. The Aptima HPV mRNA vaginal self-sampling analysis may serve as a complement in screening programs.
(Less)
- author
- Asciutto, Katrin Christine
LU
; Ernstson, Avalon
LU
; Forslund, Ola
LU
and Borgfeldt, Christer
LU
- organization
- publishing date
- 2018-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- HPV analyses, HPV mRNA, Self-collected vaginal smear, Urinary sample
- in
- Journal of Clinical Virology
- volume
- 101
- pages
- 5 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:29433016
- scopus:85041539502
- ISSN
- 1386-6532
- DOI
- 10.1016/j.jcv.2018.02.002
- language
- English
- LU publication?
- yes
- id
- de043e59-d191-46d1-8996-7cda54528190
- date added to LUP
- 2018-02-20 12:59:45
- date last changed
- 2024-06-25 12:42:22
@article{de043e59-d191-46d1-8996-7cda54528190,
abstract = {{<p>Background: In order to increase coverage in the organized cervical screening program, self-sampling with HPV analyses has been suggested. Objectives: The aim was to compare human papillomavirus (HPV) mRNA detection in vaginal and urine self-collected samples with clinician-taken cervical samples and the corresponding clinician-taken histological specimens. Study design: Self-collected vaginal, urine and clinician-taken cervical samples were analyzed from 209 women with the Aptima mRNA assay (Hologic Inc, MA, USA). Cervical cytology, colposcopy, biopsy and/or the loop electrosurgical excision procedure (LEEP) were performed in every examination. Results: The sensitivity of the HPV mRNA test in detecting high-grade squamous intraepithelial lesions (HSIL)/adenocarcinoma in situ (AIS)/cancer cases was as follows: for the vaginal self-samples 85.5% (95% CI; 75.0–92.8), the urinary samples 44.8% (95% CI; 32.6–57.4), and for routine cytology 81.7% (95% CI; 70.7–89.9). For the clinician-taken cervical HPV samples the sensitivity of the HPV mRNA test in detecting HSIL/AIS/cancer was 100.0% (95% CI; 94.9–100.0). The specificity of the HPV mRNA was similar for the clinician-taken cervical HPV samples and the self-samples: 49.0% vs. 48.1%. The urinary HPV samples had a specificity of 61.9% and cytology had a specificity of 93.3%. Conclusion: The sensitivity of the Aptima HPV mRNA test in detecting HSIL/AIS/cancer from vaginal self-samples was similar to that of routine cytology. The Aptima HPV mRNA vaginal self-sampling analysis may serve as a complement in screening programs.</p>}},
author = {{Asciutto, Katrin Christine and Ernstson, Avalon and Forslund, Ola and Borgfeldt, Christer}},
issn = {{1386-6532}},
keywords = {{HPV analyses; HPV mRNA; Self-collected vaginal smear; Urinary sample}},
language = {{eng}},
pages = {{69--73}},
publisher = {{Elsevier}},
series = {{Journal of Clinical Virology}},
title = {{Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples}},
url = {{http://dx.doi.org/10.1016/j.jcv.2018.02.002}},
doi = {{10.1016/j.jcv.2018.02.002}},
volume = {{101}},
year = {{2018}},
}